Latest News
TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US
TILT Biotherapeutics Announces First US Patient Dosed in Immunotherapy Clinical Trial in Ovarian Cancer
TILT presents a poster covering updates on TILT-T115 and TILT-T215 trials at CICON — International Cancer Immunotherapy Conference
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory NSCLC
TILT holds an oral presentation and a poster presentation covering updated on TILT-T115 trial at the SSI Annual Meeting 2022
TILT Biotherapeutics Announces over $10 Million Financing Round and Chair of the Board Appointment
TILT presents TILT-T215 interim data at ASCO 2022
New immunotherapy tools to fight cancer – An article in CORDIS on an EU founded project coordinated by TILT Biotherapeutics (available in 6 languages)
TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
TILT Biotherapeutics covered in Nature’s BioPharma Dealmakers
Upcoming Events
Please contact our business development team to meet us at the following events:
8-12th November 2021
Boston (MA, USA)